|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: NUGGC |
Gene summary for NUGGC |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | NUGGC | Gene ID | 389643 |
| Gene name | nuclear GTPase, germinal center associated | |
| Gene Alias | C8orf80 | |
| Cytomap | 8p21.1 | |
| Gene Type | protein-coding | GO ID | GO:0002237 | UniProtAcc | Q68CJ6 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 389643 | NUGGC | HCC1_Meng | Human | Liver | HCC | 4.06e-02 | -9.34e-02 | 0.0246 |
| 389643 | NUGGC | HCC2_Meng | Human | Liver | HCC | 9.14e-03 | -9.33e-02 | 0.0107 |
| 389643 | NUGGC | cirrhotic2 | Human | Liver | Cirrhotic | 1.93e-02 | -8.66e-02 | 0.0201 |
| 389643 | NUGGC | HCC1 | Human | Liver | HCC | 9.24e-13 | 1.75e+00 | 0.5336 |
| 389643 | NUGGC | HCC2 | Human | Liver | HCC | 1.30e-26 | 3.44e+00 | 0.5341 |
| 389643 | NUGGC | HCC5 | Human | Liver | HCC | 1.77e-12 | 2.86e+00 | 0.4932 |
| 389643 | NUGGC | Pt13.a | Human | Liver | HCC | 1.93e-02 | -9.34e-02 | 0.021 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00324966 | Liver | Cirrhotic | response to lipopolysaccharide | 111/4634 | 343/18723 | 8.15e-04 | 5.95e-03 | 111 |
| GO:00022376 | Liver | Cirrhotic | response to molecule of bacterial origin | 113/4634 | 363/18723 | 3.23e-03 | 1.81e-02 | 113 |
| GO:00062601 | Liver | HCC | DNA replication | 146/7958 | 260/18723 | 5.68e-06 | 7.02e-05 | 146 |
| GO:003249611 | Liver | HCC | response to lipopolysaccharide | 174/7958 | 343/18723 | 1.19e-03 | 6.62e-03 | 174 |
| GO:00712166 | Liver | HCC | cellular response to biotic stimulus | 128/7958 | 246/18723 | 1.53e-03 | 8.10e-03 | 128 |
| GO:00712226 | Liver | HCC | cellular response to lipopolysaccharide | 110/7958 | 209/18723 | 1.92e-03 | 9.77e-03 | 110 |
| GO:000223711 | Liver | HCC | response to molecule of bacterial origin | 181/7958 | 363/18723 | 2.58e-03 | 1.24e-02 | 181 |
| GO:00062751 | Liver | HCC | regulation of DNA replication | 60/7958 | 107/18723 | 3.15e-03 | 1.46e-02 | 60 |
| GO:00712196 | Liver | HCC | cellular response to molecule of bacterial origin | 113/7958 | 221/18723 | 5.73e-03 | 2.38e-02 | 113 |
| GO:0006261 | Liver | HCC | DNA-dependent DNA replication | 80/7958 | 151/18723 | 5.91e-03 | 2.44e-02 | 80 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| NUGGC | SNV | Missense_Mutation | novel | c.1992N>C | p.Gln664His | p.Q664H | Q68CJ6 | protein_coding | deleterious(0) | probably_damaging(0.979) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
| NUGGC | SNV | Missense_Mutation | c.2050G>C | p.Glu684Gln | p.E684Q | Q68CJ6 | protein_coding | tolerated(0.31) | benign(0.015) | TCGA-A8-A094-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| NUGGC | SNV | Missense_Mutation | c.1956N>C | p.Lys652Asn | p.K652N | Q68CJ6 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| NUGGC | SNV | Missense_Mutation | novel | c.713C>T | p.Ala238Val | p.A238V | Q68CJ6 | protein_coding | tolerated(0.06) | probably_damaging(0.945) | TCGA-AN-A0AS-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| NUGGC | SNV | Missense_Mutation | rs756785058 | c.2054N>A | p.Arg685Gln | p.R685Q | Q68CJ6 | protein_coding | deleterious(0.01) | benign(0.309) | TCGA-BH-A28O-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | CR |
| NUGGC | insertion | In_Frame_Ins | novel | c.648_649insACATCAGCATCTCTGGCTCCCTTTGCCTTCCGTCGCCCCCATTGT | p.Leu216_Leu217insThrSerAlaSerLeuAlaProPheAlaPheArgArgProHisCys | p.L216_L217insTSASLAPFAFRRPHC | Q68CJ6 | protein_coding | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| NUGGC | insertion | Nonsense_Mutation | novel | c.712-1_712insTTCATTGGAATTAAATTCTTTTAATTTCTATGTTCTAA | p.Ala238PhefsTer8 | p.A238Ffs*8 | Q68CJ6 | protein_coding | TCGA-AN-A0AS-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | ||
| NUGGC | SNV | Missense_Mutation | novel | c.688N>A | p.Val230Ile | p.V230I | Q68CJ6 | protein_coding | tolerated(1) | benign(0) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| NUGGC | SNV | Missense_Mutation | novel | c.2098N>A | p.Glu700Lys | p.E700K | Q68CJ6 | protein_coding | tolerated(0.35) | benign(0.023) | TCGA-DG-A2KJ-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
| NUGGC | SNV | Missense_Mutation | rs745895030 | c.859N>A | p.Val287Met | p.V287M | Q68CJ6 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-IR-A3LK-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | PD |
| Page: 1 2 3 4 5 6 7 8 9 10 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |